Mecasermin and IGF-1 LR3: different products

The Increlex label addresses growth failure in specified children with severe primary IGF-1 deficiency or certain growth-hormone gene-deletion circumstances. It is not a general replacement for growth hormone or a performance indication for healthy adults. ¹

Severe hypoglycemia, including seizures, is a major labeled risk. Hypersensitivity, intracranial hypertension and tonsillar enlargement are also relevant. Contraindications and cancer-related precautions require specialist review. Tell the specialist about headaches or breathing changes. These are consequential medical risks, not minor features of a muscle-building supplement. ¹

Changing the molecule changes the intervention. An IGF-1-related name does not establish equivalent exposure, safety or clinical benefit. A reference for LR3 needs direct product-specific evidence and cannot use the existence of mecasermin to imply FDA approval or routine patient access.

Mecasermin is the active ingredient in Increlex, approved for growth failure in children with severe primary IGF-1 deficiency or growth-hormone gene deletion with neutralizing antibodies. It is not a general short-stature, bodybuilding, recovery or anti-aging medicine. Diagnosis and treatment require pediatric endocrine expertise. The label excludes use for secondary IGF-1 deficiency, including malnutrition, hypothyroidism or chronic glucocorticoid treatment, where the underlying cause should be addressed. ¹

Mecasermin can cause severe hypoglycemia, including seizures, and has meal-related administration and glucose-monitoring precautions. Intracranial hypertension, enlarged tonsillar or lymphoid tissue, slipped capital femoral epiphysis, scoliosis progression and malignant neoplasia are important risks. Headache with vision change, vomiting, seizure, limping, hip or knee pain, breathing problems during sleep or a new mass requires prompt assessment. Treatment is contraindicated with active or suspected malignancy. ¹

IGF-1 LR3 is a modified, longer-acting analog and is not Increlex. A similar name or action at the IGF-1 receptor does not establish equal exposure, purity, benefit or safety. Research vials sold for muscle gain cannot borrow pediatric mecasermin approval, and a certificate of analysis does not create human clinical evidence. Combining LR3 with growth-hormone secretagogues may increase uncertainty and hypoglycemia or growth-related concerns. No patient protocol should be inferred from the Increlex label. ¹

Increlex instructions connect administration with food because hypoglycemia can be severe. Children should have caregiver supervision and activity precautions when low glucose is possible. These label safeguards cannot be copied into an LR3 protocol because the molecule and exposure differ. A research seller does not provide pediatric endocrine diagnosis, glucose monitoring or emergency planning, and no amount of label borrowing makes the research analog an approved product. Keep prescribed rescue instructions available wherever the child receives a dose. ¹